Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.
Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.
复制标题
DOI：
10.1016/j.ijrobp.2021.12.176
复制
发表时间：
2022-05-01
影响因子：
7
通讯作者：
Green, Michael D.
中科院分区：
文献类型：
--
作者：
Bryant, Alex K.;Sankar, Kamya;Strohbehn, Garth W.;Zhao, Lili;Elliott, David;Daniel, Victoria;Ramnath, Nithya;Green, Michael D.
目前尚不清楚从放疗（RT）完成到durvalumab的时间是否会影响接受确定性放化疗和辅助durvalumab治疗的III期非小细胞肺癌（NSCLC）的结局。使用美国退伍军人健康管理局数据库，我们回顾性地确定了728例接受确定性放化疗的III期NSCLC患者，这些患者在放疗完成后120天内开始durvalumab治疗。在多变量考克斯回归模型中分析末次放射治疗与首次输注度伐鲁单抗之间的时间，以获得无进展生存期（PFS）和总生存期（OS）的主要结局，并根据基线患者和疾病特征进行调整。主要分析使用120天标志，从放疗完成后120天开始测量OS和PFS。在728例患者中，从RT完成至durvalumab开始的中位时间为41天（四分位距[IQR] 30-58）。在多变量考克斯回归分析中，RT完成至开始度伐鲁单抗治疗的时间与PFS（校正风险比[aHR] 1.01/周，95%置信区间[CI] 0.98-1.04，p=0.4）或OS（aHR 1.02/周，95% CI 0.98-1.06，p=0.3）无关。RT后≤ 14天开始度伐鲁单抗治疗也与PFS或OS改善无关。在不同分析技术的敏感性分析中，结果稳健。在该真实世界患者队列中，RT完成后120天内开始度伐鲁单抗治疗的时间与PFS或OS无关。
It is unclear whether time from radiation (RT) completion to durvalumab influences the outcomes of stage III non-small-cell lung cancer (NSCLC) treated with definitive chemoradiation and adjuvant durvalumab. Using the United States Veterans Health Administration database, we retrospectively identified 728 patients with stage III NSCLC treated with definitive chemoradiation who started durvalumab within 120 days of radiation completion. Time between the last radiation treatment and first durvalumab infusion was analyzed in multivariable Cox regression models for the primary outcomes of progression-free survival (PFS) and overall survival (OS), adjusting for baseline patient and disease characteristics. The primary analysis used a 120-day landmark, measuring OS and PFS from 120 days after radiation completion. Among 728 patients, the median time from RT completion to durvalumab start was 41 days (interquartile range [IQR] 30–58). In multivariable Cox regression, time from RT completion to durvalumab start showed no association with PFS (adjusted hazard ratio [aHR] 1.01 per week, 95% confidence interval [CI] 0.98–1.04, p=0.4) or OS (aHR 1.02 per week, 95% CI 0.98–1.06, p=0.3). Starting durvalumab ≤ 14 days after RT was also not associated with improved PFS or OS. Results were robust in sensitivity analyses varying analytical technique. Timing of durvalumab initiation up to 120 days after RT completion is not associated with PFS or OS in this real-world patient cohort.
登录
查看更多内容
DOI：
10.1136/bmj.h5651
发表时间：
2015-11-04
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Burke JF;Sussman JB;Kent DM;Hayward RA
通讯作者：
Hayward RA
影响因子：
5.2
作者：
Sankar K;Bryant AK;Strohbehn GW;Zhao L;Elliott D;Moghanaki D;Kelley MJ;Ramnath N;Green MD
通讯作者：
Green MD
影响因子：
158.5
作者：
Antonia, S. J.;Villegas, A.;Ozguroglu, M.
通讯作者：
Ozguroglu, M.
DOI：
10.1016/0021-9681(87)90171-8
发表时间：
1987-01-01
期刊：
JOURNAL OF CHRONIC DISEASES
影响因子：
--
作者：
CHARLSON, ME;POMPEI, P;MACKENZIE, CR
通讯作者：
MACKENZIE, CR
影响因子：
158.5
作者：
Antonia, S. J.;Villegas, A.;Ozguroglu, M.
通讯作者：
Ozguroglu, M.